Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Current Topics in Pharmacology   Volumes    Volume 24 
Pharmacology and scheduling of Temozolomide
Giorgio Attinà, Silvia Triarico, Michele Antonio Capozza, Alberto Romano, Palma Maurizi, Stefano Mastrangelo, Antonio Ruggiero
Pages: 61 - 68
Number of pages: 8
Current Topics in Pharmacology
Volume 24 

Copyright © 2020 Research Trends. All rights reserved

Temozolomide (TMZ) is an alkylating drug, belonging to the family of derivatives of Imidazotetrazinone. Pre-clinical studies showed that TMZ has a good bioavailability after oral administration and is able to cross the blood-brain barrier. Due to these peculiar pharmaco-dynamic features, TMZ has been first adopted in the treatment of malignant brain tumors. The clinical use of TMZ has shown that the drug has a negligible toxicity and its antitumor activity is “schedule-dependent”. Therefore, many schedules of TMZ administration have been developed in order to investigate and ameliorate its antitumoral efficacy. A higher response rate was detected when the TMZ total dose is administered over 5 days. Recently, the activity of TMZ in combination with different antineoplastic agents is under investigation in children and adults in order to test its activity in malignant tumours other than brain tumors.
View Full Article  


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms